04 August 2023
04 August 2023
Net income was impacted by $525m in legal settlement accrual.
The round extension pushes the Series B total to $145m, with plans for the first clinical data readout in H2 2023.
Ervebo initially received approval in December 2019 for use in those aged 18 years and above.
The bulk order aims to replenish the US stockpile used for the 2022 mpox outbreak.
Novartis will exclusively develop and commercialise a next-generation Lp(a) therapy.
bit.bio utilises opti-ox to rapidly facilitate TF-mediated transformation of iPSCs into highly defined cell types.
AAHI is developing a novel RNA vaccine that overcomes manufacturing and storage limitations to increase accessibility.
As the US Solicitor General takes aim at the Sacklers, another infamous pharma head is back with a new project.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
